Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10836507 | 0.80 | ESR1 (0.45) | ESR1ACP3GAATSHRACHE | |
| SCHEMBL5697209 | 0.80 | TSHR (0.50) | ESR1ACP3GAATSHRACHE | |
| SCHEMBL198213 | 0.80 | TSHR (0.50) | ESR1ACP3GAATSHRACHE | |
| SCHEMBL13993318 | 0.80 | ESR1 (0.59) | ESR1ACP3GAATSHRACHE | |
| SCHEMBL30507724 | 0.78 | ESR1 (0.56) | ESR1ACP3GAATSHRACHE | |
| SCHEMBL4429090 | 0.77 | GABRA1 (0.48) | TSHRALDH1A1MEN1LMNAMAPT | |
| SCHEMBL9165861 | 0.77 | ESR1 (0.46) | ESR1ACP3GAATSHRACHE | |
| SCHEMBL910441 | 0.77 | ESR1 (0.46) | ESR1ACP3GAATSHRACHE | |
| SCHEMBL9698743 | 0.77 | CA1 (0.46) | TSHRACHEALDH1A1LMNAKMT2A | |
| SCHEMBL8943608 | 0.76 | CES2 (0.48) | GAAALDH1A1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1064285-B1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | STRAGEN PHARMA SA (CH) | 2005-02-16 | — | — | EP | claimed |
| EP-1064285-A1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | Oncopharm Corporation (US) | 2001-01-03 | — | — | EP | claimed |
| WO-1999048894-A1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | ONCOPHARM CORPORATION (US) | 1999-09-30 | — | — | WO | claimed |
| US-RE45128-E1 | Cephalotaxane derivatives and their processes of preparation and purification | IVAX International GmbH (CH) | 2014-09-09 | — | — | US | disclosed |
| US-7842687-B2 | Natural, synthetic or semi-synthetic crude harringtonines purified by chromatography and crystallization in which the solvent is water or lower C1-4 alkanol or an aqueous mixture of organic solvents; treatment of cancer through oral administration | CHEMGENEX PHARMACEUTICALS, INC. (AU) | 2010-11-30 | — | — | US | disclosed |
| US-7169774-B2 | Cephalotaxane derivatives and their processes of preparation and purification | STRAGEN PHARMA S.A. (CH) | 2007-01-30 | — | — | US | disclosed |
| US-20060234999-A1 | Cephalotaxane derivatives and their processes of preparation and purification | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2006-10-19 | — | — | US | disclosed |
| US-20050090484-A1 | Cephalotaxane derivatives and their processes of preparation and purification | IVAX International GmbH (CH) | 2005-04-28 | — | — | US | disclosed |
| EP-1064285-B1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | STRAGEN PHARMA SA (CH) | 2005-02-16 | — | — | EP | disclosed |
| US-6831180-B1 | Substituted tertiary carboxylic oxacycloalkane acids, used to prepare anhydro-homo-harringtonic acids by semi-synthesis; hydroxyl function of a cephalotaxane is esterified with a 2-carboxyl-2-alkyl-1-oxacycloalkane claimed intermediate; (indexing from 7169774 added) | STRAGEN PHARMA SA. (CH) | 2004-12-14 | — | — | US | disclosed |
| US-6613900-B2 | Asymetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. | ONCOPHARM CORPORATION | 2003-09-02 | — | — | US | disclosed |
| US-20020045750-A1 | Asymetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. | IVAX International GmbH (CH) | 2002-04-18 | — | — | US | disclosed |
| EP-1064285-A1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | Oncopharm Corporation (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999048894-A1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | ONCOPHARM CORPORATION (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234999-A1 | Cephalotaxane derivatives and their processes of preparation and purification | UGT1A7, CYP8B1, UGT2B7 | ESR1 4758/4885ACP3 2299/4885GAA 1517/4885 |
| US-20020045750-A1 | Asymetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. | AAAS, AARS1, AADAT | ESR1 4814/4885ACP3 1195/4885GAA 690/4885 |
| US-20050090484-A1 | Cephalotaxane derivatives and their processes of preparation and purification | UGT1A7, CYP8B1, UGT2B7 | ESR1 4758/4885ACP3 2299/4885GAA 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.